Search
Search
About
Log in
Join
Experiences with
Lymphocytic leukemia
Posts
Communities
3,090 public posts
Filter results
Test Before Treat
Test Before Treat™ Although this comes from the USA, the logic and reasoning can apply to any international patient and medical professionals. https://cllsociety.org/wp-content/uploads/2019/08/Test-Before-Treat-One-pager-V3.pdf "More Patients Spill the Beans on their Test Before Treat™ Experiences
Test Before Treat™ Although this comes from the USA, the logic and reasoning can apply to any international patient and medical professionals. https://cllsociety.org/wp-content/uploads/2019/08/Test-Before-Treat-One-pager-V3.pdf "More Patients Spill the Beans on their Test Before Treat™ Experiences
lankisterguy
Volunteer
in
CLL Support
5 years ago
Potential Early Drivers of Disease in Treatment-Naive CLL Identified
[/i] By determining the relationship between a set of somatic mutations and established prognostic clinical features with time-to-first treatment (TTFT), study researchers identified potential early drivers of disease among treatment-naive chronic
lymphocytic
leukemia
(TN CLL) patients.
[/i] By determining the relationship between a set of somatic mutations and established prognostic clinical features with time-to-first treatment (TTFT), study researchers identified potential early drivers of disease among treatment-naive chronic
lymphocytic
leukemia
(TN CLL) patients.
Jm954
Administrator
in
CLL Support
5 years ago
Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease.
December 8, 2019 ASH poster. There are lots of us on long term Ibrutinib who have had a good response but still have a small amount of residual disease. I would welcome the chance to add venetoclax to my treatment as in this study which is an important piece of work by Michael J Keating et al. "[i]Patients
December 8, 2019 ASH poster. There are lots of us on long term Ibrutinib who have had a good response but still have a small amount of residual disease. I would welcome the chance to add venetoclax to my treatment as in this study which is an important piece of work by Michael J Keating et al. "[i]Patients
Jm954
Administrator
in
CLL Support
5 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Transformation Confirmed - Likely Richter’s
My doctor called yesterday and confirmed my PET from last week shows definite transformation and the PA called today to say it’s likely Richter’s (forgot to ask if confirmed by the biopsy - still shock) and they want to start treatment this week. I’m headed back to Houston for consult and planning.
My doctor called yesterday and confirmed my PET from last week shows definite transformation and the PA called today to say it’s likely Richter’s (forgot to ask if confirmed by the biopsy - still shock) and they want to start treatment this week. I’m headed back to Houston for consult and planning.
SarasotaPaul
in
CLL Support
5 years ago
Does taking Nplate causes nose bleed ?
I'm currently in week 3 of taking Nplate. It could boost my platelet count to 32 however I have nosebleed sometimes recently. I was wondering if it's a side effect of NPlate or something serious?
I'm currently in week 3 of taking Nplate. It could boost my platelet count to 32 however I have nosebleed sometimes recently. I was wondering if it's a side effect of NPlate or something serious?
farasad2001
in
ITP Support Association
5 years ago
Duvelisib Dosing Modification Does Not Compromise Efficacy in Heavily Pretreated CLL/SLL
Reducing or interrupting duvelisib (Copiktra) treatment does not increase toxicity or reduce outcomes with relapsed/refractory chronic
lymphocytic
leukemia
/small
lymphocytic
lymphoma (CLL/SLL).
Reducing or interrupting duvelisib (Copiktra) treatment does not increase toxicity or reduce outcomes with relapsed/refractory chronic
lymphocytic
leukemia
/small
lymphocytic
lymphoma (CLL/SLL).
Jm954
Administrator
in
CLL Support
5 years ago
Long time DX,SORT TIME TMT
I was diagnosed with CLL in 1995. I’ve been on W&W until this year in Sept. at age 86. Treatment was initiated Ibrutinib 140mg, orally per diem. I’ve positive movement with my numbers and the splenomegaly. My nodes were minimally involved. My side effects have been undetectable. Given good response
I was diagnosed with CLL in 1995. I’ve been on W&W until this year in Sept. at age 86. Treatment was initiated Ibrutinib 140mg, orally per diem. I’ve positive movement with my numbers and the splenomegaly. My nodes were minimally involved. My side effects have been undetectable. Given good response
desti
in
CLL Support
5 years ago
No fear and so grateful for Mutation diagnoses
So for the past eight years since starting treatment for ET I was in chronic all over skeletal pain also neurological (all from medication as I had NO pain before). I now have Myelofibrosis and to be honest am over the moon!! Instead of it being a negative it’s like I have a life worth living again.
So for the past eight years since starting treatment for ET I was in chronic all over skeletal pain also neurological (all from medication as I had NO pain before). I now have Myelofibrosis and to be honest am over the moon!! Instead of it being a negative it’s like I have a life worth living again.
StreetPastor
in
MPN Voice
5 years ago
Dr Michael Keating's Story - Taking CLL Therapies From Bedside to Community
A fascinating overview of one of the giants in CLL research, who provided many of us with the first treatment capable of prolonging life expectancy (FCR) and for about 60% of those who are mutated IgHV, effectively a cure. From humble beginnings in Melbourne Australia, to a fulfilling career at the
A fascinating overview of one of the giants in CLL research, who provided many of us with the first treatment capable of prolonging life expectancy (FCR) and for about 60% of those who are mutated IgHV, effectively a cure. From humble beginnings in Melbourne Australia, to a fulfilling career at the
AussieNeil
Partner
in
CLL Support
5 years ago
IVGH results
Hello. I am new to the group, just diagnosed this month. My last CBC showed absolute lymphocytes at 5280. I was feeling pretty good after my doctor explained what CLL is, how it progresses etc. But today I got results of another test back with the following: IVGH Borderline Mutated Mutation Rate 3.0
Hello. I am new to the group, just diagnosed this month. My last CBC showed absolute lymphocytes at 5280. I was feeling pretty good after my doctor explained what CLL is, how it progresses etc. But today I got results of another test back with the following: IVGH Borderline Mutated Mutation Rate 3.0
lmav
in
CLL Support
5 years ago
Clinical Utility of Chromosomal Microarray in Richter's Transformation
Chromosomal microarray (CMA) is clever, very sensitive technology which looks for extra (duplicated) or missing (deleted) chromosomal segments, sometimes called copy number variants (CNVs) - see illustration. These include: microdeletions and microduplications of chromosome segments, which are too
Chromosomal microarray (CMA) is clever, very sensitive technology which looks for extra (duplicated) or missing (deleted) chromosomal segments, sometimes called copy number variants (CNVs) - see illustration. These include: microdeletions and microduplications of chromosome segments, which are too
Jm954
Administrator
in
CLL Support
5 years ago
A Conversation with Dr Tam about Zanubrutinib: A Novel BTK Inhibitor
More here: https://www.hematologyandoncology.net/archives/january-2019/zanubrutinib-a-novel-btk-inhibitor-in-chronic-
lymphocytic
-
leukemia
-and-non-hodgkin-lymphoma/ Jackie
More here: https://www.hematologyandoncology.net/archives/january-2019/zanubrutinib-a-novel-btk-inhibitor-in-chronic-
lymphocytic
-
leukemia
-and-non-hodgkin-lymphoma/ Jackie
Jm954
Administrator
in
CLL Support
5 years ago
Researchers examine the metabolic effects of an oral blood cancer drug ~ RUXOLITINIB (Jakafi)
Post by MPN-MATE Admin » Wed Nov 13, 2019 11:14 am NOV. 12, 2019
Researchers examine the metabolic effects of an oral blood cancer drug...
by The Mount Sinai Hospital Hi guys... This report from the Mount Sinai Hospital is yet to be properly validated. However, many of us may have already read
Post by MPN-MATE Admin » Wed Nov 13, 2019 11:14 am NOV. 12, 2019
Researchers examine the metabolic effects of an oral blood cancer drug...
by The Mount Sinai Hospital Hi guys... This report from the Mount Sinai Hospital is yet to be properly validated. However, many of us may have already read
socrates_8
in
MPN Voice
5 years ago
CALQUENCE gets FDA approval for treating CLL
The latest approval for Calquence (acalabrutinib), a Bruton tyrosine kinase (BTK) inhibitor, was granted under the FDA’s Real-Time Oncology Review and newly established Project Orbis programs. Calquence binds covalently to BTK, thereby inhibiting its activity. In B-cells, BTK signaling results in activation
The latest approval for Calquence (acalabrutinib), a Bruton tyrosine kinase (BTK) inhibitor, was granted under the FDA’s Real-Time Oncology Review and newly established Project Orbis programs. Calquence binds covalently to BTK, thereby inhibiting its activity. In B-cells, BTK signaling results in activation
Myrddin
in
CLL Support
5 years ago
MRD assessment in CLL
ASCO 2019 | MRD assessment in CLL - Dr Danielle Brander Measurable residual disease is playing a larger role in treatment assessment of chronic
lymphocytic
leukemia
(CLL). This topic is explored by Danielle Brander, MD, of the Duke University School of Medicine, Durham, NC.
ASCO 2019 | MRD assessment in CLL - Dr Danielle Brander Measurable residual disease is playing a larger role in treatment assessment of chronic
lymphocytic
leukemia
(CLL). This topic is explored by Danielle Brander, MD, of the Duke University School of Medicine, Durham, NC.
Jm954
Administrator
in
CLL Support
5 years ago
Sequential and combination treatments with novel agents in chronic lymphocytic leukemia (including target illustration) - Oct 2019
This paper by Moritz Fürstenau, Michael Hallek and Barbara Eichhorst, per the recent post by avzuclav, provides a very readable overview of the current situation with respect to the challenges of continued monotherapy on Ibrutinib and subsequent investigations to determine the best multi-drug treatment
This paper by Moritz Fürstenau, Michael Hallek and Barbara Eichhorst, per the recent post by avzuclav, provides a very readable overview of the current situation with respect to the challenges of continued monotherapy on Ibrutinib and subsequent investigations to determine the best multi-drug treatment
AussieNeil
Partner
in
CLL Support
5 years ago
Cancer Fatigue and Getting Through the Holidays
The Leukemia & Lymphoma Society is offering a Free Telephone Support Program for Patients Families and Caregivers. - Click this link to register: https://pburkhard.wufoo.com/forms/qrfew60160p1a4/ or http://bit.ly/DecLnL. Cancer Fatigue and Getting Through the Holidays When: Wednesday
The Leukemia & Lymphoma Society is offering a Free Telephone Support Program for Patients Families and Caregivers. - Click this link to register: https://pburkhard.wufoo.com/forms/qrfew60160p1a4/ or http://bit.ly/DecLnL. Cancer Fatigue and Getting Through the Holidays When: Wednesday
lankisterguy
Volunteer
in
CLL Support
5 years ago
Blood cancers: New generation stem cell transplant significantly reduces complications for patients
Post by MPN-MATE Admin » Wed Nov 06, 2019 9:21 am Hey everyone... :-) More great good news is coming our way... This article has already successfully run 'Human Trials', and in the USA, it's about to be accepted by the FDA for a Phase III Clinical Trial... Impressive results as you will see from reading
Post by MPN-MATE Admin » Wed Nov 06, 2019 9:21 am Hey everyone... :-) More great good news is coming our way... This article has already successfully run 'Human Trials', and in the USA, it's about to be accepted by the FDA for a Phase III Clinical Trial... Impressive results as you will see from reading
socrates_8
in
MPN Voice
5 years ago
6 Videos from OncLive - Drs. Flinn, Davids, Kahl, & Pagel - Focus on Chemo Free Frontline Treatments
- Acalabrutinib's Role in Treating Chronic
Lymphocytic
Leukemia
https://onclive.createsend1.com/t/j-l-mktuhky-jrtrfkhuh-p/ Turning to data from ASCEND and ELEVATE-TN, the panel provides perspective on acalabrutinib therapy for patients with chronic
lymphocytic
leukemia
.
- Acalabrutinib's Role in Treating Chronic
Lymphocytic
Leukemia
https://onclive.createsend1.com/t/j-l-mktuhky-jrtrfkhuh-p/ Turning to data from ASCEND and ELEVATE-TN, the panel provides perspective on acalabrutinib therapy for patients with chronic
lymphocytic
leukemia
.
lankisterguy
Volunteer
in
CLL Support
5 years ago
Extensive body heat.
Anyone with Myelofibrosis on Jakafi experiencing occasional internal body heat like if you are burning inside?
Anyone with Myelofibrosis on Jakafi experiencing occasional internal body heat like if you are burning inside?
Boriqua
in
MPN Voice
5 years ago
1
...
70
71
72
...
100
Next page
30
40
50
60
70
80
90
100
Filter results
Clear filters
Posted in
All communities
CLL Support
1940 results
MPN Voice
789 results
Leukaemia Support
168 results
View top 10 communities
Sort by
Most Relevant
Newest